GlassScriptPhysician profile
Pratik V Desai
NPI 1588652283
$10,382.26
in general payments reported to CMS, 2019-2025
47 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $1,624 · 2021: $1,866 · 2022: $1,478 · 2023: $1,250 · 2024: $1,507 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,327.55 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $1,089.99 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,076.69 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $958.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $827.71 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $735.51 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.57 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $576.13 | 2020-2025 | Nexletol, Nexlizet |
| Novo Nordisk INC | $342.42 | 2019-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $329.44 | 2019-2024 | |
| Baxter Healthcare | $286.93 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cardiovascular Systems INC. | $245.72 | 2020-2022 | |
| Amarin Pharma, INC. | $231.59 | 2019-2022 | |
| Recor Medical INC | $152.15 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abbott Laboratories | $133.91 | 2020-2025 | Cardiomems |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.